Federated Hermes Inc. Lowers Stock Holdings in Eli Lilly and Company $LLY

Federated Hermes Inc. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 44.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 124,290 shares of the company’s stock after selling 97,491 shares during the quarter. Federated Hermes Inc.’s holdings in Eli Lilly and Company were worth $94,833,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Vanguard Group Inc. increased its position in Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares during the last quarter. Laurel Wealth Advisors LLC grew its stake in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the period. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $8,827,714,000. Jennison Associates LLC increased its holdings in shares of Eli Lilly and Company by 4.3% during the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after buying an additional 226,620 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Eli Lilly and Company by 2.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after buying an additional 103,119 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on LLY. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Wolfe Research raised their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Scotiabank started coverage on shares of Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price target for the company. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $1,173.91.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,024.14 on Thursday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm has a market capitalization of $968.20 billion, a P/E ratio of 50.10, a P/E/G ratio of 0.79 and a beta of 0.35. The company’s fifty day moving average price is $1,057.65 and its two-hundred day moving average price is $886.06.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the firm earned $1.18 earnings per share. The company’s revenue was up 53.9% on a year-over-year basis. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Large AI and oncology upside — company coverage highlights a ~$1B collaboration with Nvidia to accelerate drug discovery and an expanded oncology pipeline (including recent regulatory advances) that could fuel 2026 revenue and pipeline value. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Positive Sentiment: Major gene‑editing collaboration — Lilly signed a deal worth up to ~$1.12B with Seamless Therapeutics to develop programmable recombinase therapies for hearing loss, expanding durable‑therapy optionality on its R&D roadmap. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Positive Sentiment: Strong earnings track record — multiple Zacks pieces flag Lilly’s history of earnings beats and Wall Street expectations for EPS growth ahead of the next report, supporting potential near‑term upside on another beat. Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Investor narratives and bullish research — several analyst and bull‑case writeups point to LLY as a long‑term growth name (GLP‑1 leadership, oncology, AI), which supports a buy thesis but is dependent on execution. Eli Lilly and Company (LLY): A Bull Case Theory 
• Neutral Sentiment: Stock is a market focus heading into results — trending coverage and investor interest mean LLY may be more volatile around catalysts (earnings, pipeline readouts). Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
• Negative Sentiment: Intense GLP‑1 competition — data show Novo Nordisk more than doubled U.S. ad spend versus Lilly for Wegovy/Ozempic vs Lilly’s GLP‑1s, implying potential market‑share pressure and the need for higher marketing investment. Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
• Negative Sentiment: Drug‑pricing and policy risk — Medicare named several Lilly drugs (including Verzenio) for upcoming price negotiations, which could compress pricing on selected products. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Regulatory/operational pushback — hospital groups are contesting a new Lilly 340B claims‑data policy, a dispute that could lead to reputational, contractual or policy‑level headwinds. AHA urges HRSA to stop Eli Lilly’s 340B claims-data submission policy from going into effect
• Negative Sentiment: Immediate market reaction mixed — some coverage notes LLY shares fell even after the gene‑editing announcement, suggesting investors are focusing on near‑term risks (competition, pricing) over long‑term deals. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.